Nolan Polson on Leading Through Juno, Celgene, BMS and Beyond

In today’s episode I was joined by Nolan Polson, Vice President of Quality Assurance and Product Quality at Iovance Biotherapeutics.

I really wanted to speak to Nolan because he’s one of the few leaders who’s built quality teams at every stage – from biologics at Amgen to radiopharma at Janssen, to launching two first-in-class cell therapies at Juno/Celgene/BMS.

Nolan’s career path is a great example of what it looks like to carry foundational quality principles into fast-paced, high-growth settings. He talks about his early scientific passion, how he transitioned from R&D to Quality Ops, and the leadership mindset required to scale from clinical to commercial.

We talk about the following:

• How Nolan's scientific roots in chemistry shaped his quality mindset
• Transitioning from R&D into Quality Ops and building speed with structure
• What Big Pharma taught him about good science, mature systems, and agency collaboration
• Scaling product quality teams from 2 to 45 during two cell therapy launches
• Building empowered leadership teams and the traits he looks for when hiring
• How AI can help quality teams move toward review-by-exception and proactive oversight
• The difference between biologics and cell therapy mindsets in a commercial setting
• Creating a culture of continuous learning and succession planning
• Lessons from moving across Amgen, J&J, GSK, BMS, and Iovance
• Why autologous cell therapy still holds massive curative potential

Nolan is a thoughtful, experienced quality leader who blends deep scientific expertise with a calm, strategic leadership approach.

Thank you Nolan for sharing your incredible journey.

Hope everyone enjoys the show!